Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison Sells 1,100 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the transaction, the executive vice president owned 14,272 shares in the company, valued at $2,161,922.56. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $147.40 on Friday. The stock has a market capitalization of $40.62 billion, a price-to-earnings ratio of 37.32, a PEG ratio of 10.46 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The stock’s 50 day moving average price is $150.21 and its two-hundred day moving average price is $174.25. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the prior year, the business earned $3.35 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several large investors have recently bought and sold shares of the stock. Crux Wealth Advisors lifted its stake in Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after acquiring an additional 49 shares in the last quarter. Larson Financial Group LLC lifted its stake in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after acquiring an additional 53 shares in the last quarter. Camelot Portfolios LLC lifted its stake in Becton, Dickinson and Company by 1.5% during the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC lifted its stake in Becton, Dickinson and Company by 3.6% during the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after acquiring an additional 55 shares in the last quarter. Finally, Atlantic Union Bankshares Corp lifted its stake in Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after acquiring an additional 57 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BDX has been the topic of a number of recent research reports. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. TD Cowen cut their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Stifel Nicolaus cut their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Finally, Piper Sandler cut their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $183.64.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.